Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010. Celldex and Pfizer Vaccines LLC entered into a global development and commercialization agreement in April 2008 for rindopepimut, an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM). Pfizer has informed Celldex that the rindopepimut program is no longer a strategic priority of Pfizer and has terminated the agreement. As previously disclosed, across three clinical studies, rindopepimut has met or exceeded all pre-determined safety and efficacy objectives. Shares of Celldex Therapeutics slumped more than 35% in pre-market trading.
Walgreen Co. (NYSE: WAG) said Friday that its same-store sales rose 2.1% in August.
Canada's Goldcorp Inc. (NYSE: GG) on Friday agreed to acquire Andean Resources Ltd. for about 3.6 billion Canadian dollars ($3.42 billion). Andean's principal asset is the 100%-owned Cerro Negro gold project, an advanced-stage, high-grade vein system located in the Santa Cruz province of Argentina.
Disclosure: Author doesn't own any of the stocks discussed here.
